- Home
- GF vs CUE Comparison
GF vs CUE Comparison
Compare GF & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GF | CUE |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.1M | 177.0M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | GF | CUE |
|---|---|---|
| Price | $10.25 | $21.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $88.00 |
| AVG Volume (30 Days) | 22.2K | ★ 153.2K |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $9.98 | $0.17 |
| 52 Week High | $12.49 | $45.50 |
Technical Indicators
Market Signals| Indicator | GF | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 43.02 | 47.86 |
| Support Level | $10.14 | $17.06 |
| Resistance Level | $10.49 | $33.95 |
| Average True Range (ATR) | 0.14 | 2.33 |
| MACD | 0.03 | 0.45 |
| Stochastic Oscillator | 56.76 | 41.30 |
Price Performance
Historical ComparisonAbout GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investments includes investments in different sectors such as the industrials, information technology, materials, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.